Bank of New York Mellon’s Moderna MRNA Stock Holding History

Bank of New York Mellon’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119M	Buy	1,701,675 +10,470	+0.6%	+$542K	0.02%	588
2026 Q1	$85.9M	Sell	1,691,205 -38,053	-2%	-$1.78M	0.02%	712
2025 Q4	$51M	Sell	1,729,258 -33,432	-2%	-$908K	0.01%	984
2025 Q3	$45.5M	Buy	1,762,690 +150,731	+9%	+$4.2M	0.01%	1079
2025 Q2	$44.5M	Sell	1,611,959 -306,289	-16%	-$8.07M	0.01%	1076
2025 Q1	$54.4M	Buy	1,918,248 +34,034	+2%	+$1.21M	0.01%	919
2024 Q4	$78.3M	Sell	1,884,214 -253,068	-12%	-$12.1M	0.01%	763
2024 Q3	$143M	Sell	2,137,282 -133,466	-6%	-$12.3M	0.03%	490
2024 Q2	$270M	Sell	2,270,748 -35,228	-2%	-$4.46M	0.05%	297
2024 Q1	$246M	Sell	2,305,976 -53,451	-2%	-$5.39M	0.05%	330
2023 Q4	$235M	Sell	2,359,427 -63,179	-3%	-$5.31M	0.05%	336
2023 Q3	$250M	Sell	2,422,606 -30,609	-1%	-$3.41M	0.06%	310
2023 Q2	$298M	Sell	2,453,215 -100,010	-4%	-$13.3M	0.06%	279
2023 Q1	$392M	Sell	2,553,225 -71,274	-3%	-$11.8M	0.09%	216
2022 Q4	$471M	Sell	2,624,499 -46,209	-2%	-$7.56M	0.11%	185
2022 Q3	$316M	Sell	2,670,708 -71,455	-3%	-$10.8M	0.08%	234
2022 Q2	$392M	Buy	2,742,163 +93,359	+4%	+$13.3M	0.09%	205
2022 Q1	$456M	Sell	2,648,804 -71,251	-3%	-$12M	0.09%	201
2021 Q4	$691M	Buy	2,720,055 +2,350	+0.1%	+$687K	0.12%	143
2021 Q3	$1.05B	Buy	2,717,705 +1,319,143	+94%	+$487M	0.2%	92
2021 Q2	$329M	Buy	1,398,562 +122,435	+10%	+$21.9M	0.06%	272
2021 Q1	$167M	Sell	1,276,127 -16,961	-1%	-$2.46M	0.03%	464
2020 Q4	$135M	Buy	1,293,088 +30,262	+2%	+$3.06M	0.03%	520
2020 Q3	$89.3M	Buy	1,262,826 +196,693	+18%	+$13.7M	0.02%	616
2020 Q2	$68.5M	Buy	1,066,133 +416,540	+64%	+$22.8M	0.02%	711
2020 Q1	$19.5M	Buy	649,593 +66,479	+11%	+$1.53M	0.01%	1307
2019 Q4	$11.4M	Buy	583,114 +82,269	+16%	+$1.46M	﹤0.01%	1897
2019 Q3	$7.97M	Buy	500,845 +456,007	+1,017%	+$6.74M	﹤0.01%	2046
2019 Q2	$657K	Buy	44,838 +14,110	+46%	+$303K	﹤0.01%	3466
2019 Q1	$625K	Buy	+30,728	New	+$570K	﹤0.01%	3438

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Bank of New York Mellon's MRNA Position: Q2 2026 in Review

Bank of New York Mellon increased its Moderna (MRNA) stake by 0.62% in Q2 2026, buying an estimated $542K and bringing the position to 1,701,675 shares worth $119M. The position accounts for 0.02% of the portfolio, ranked #588.

Bank of New York Mellon first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.05B in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Bank of New York Mellon held 1,701,675 shares of Moderna worth $119M as of Q2 2026.
Bank of New York Mellon bought 10,470 Moderna shares in Q2 2026, an estimated $542K.
Moderna made up 0.02% of Bank of New York Mellon's portfolio in Q2 2026, its #588 holding.
Bank of New York Mellon first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
Bank of New York Mellon's Moderna position peaked at $1.05B in Q3 2021.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.